NEWS
Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer
A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab (Herceptin) may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial. These results, the first from a large randomized breast cancer trial to test nonanthracycline chemotherapy with trastuzumab, were reported October 6 in the New England Journal of Medicine. Read more > >
Higher-Dose Radiation Does Not Improve Survival in Some Lung Cancer Patients
High-dose radiation arms of clinical trial closed based on findingsBRCA Gene Mutations May Influence Survival, Treatment Response in Ovarian Cancer
Results suggest new approach for testing potential treatmentsNewer Cancer Drugs May Cause Thyroid to Function Abnormally
Thyroid abnormalities may be a common side effect of targeted drugs and immunotherapiesBacterium Linked to Colorectal Cancer in Two Independent Studies
Both research teams found an overabundance of Fusobacterium in tumor samples
SCIENCE SNAPSHOT
What is this? Click on the image to find out.
IN DEPTH
Vitamin E Supplements Tied to Increased Risk of Prostate Cancer
Longer follow-up from SELECT trial reveals greater risk
After DES: Tracking the Harms of a Prenatal Drug Exposure
Researchers document the health risks associated with a drug once used in pregnancy
Profiles in Cancer Research: Dr. Samuel Achilefu
The Washington University researcher is developing imaging probes to visualize tumor margins and monitor the effects of cancer treatment
Featured Clinical Trial: Bortezomib and Chemotherapy for Systemic Light-Chain Amyloidosis
Will adding bortezomib to chemotherapy improve outcomes for patients?
Cancer Center Profile: Purdue University Center for Cancer Research
The center has been studying cancer mechanisms and developing cancer treatments since 1978
UPDATES
AHRQ Update
- Public Comment Sought on Draft Prostate Cancer Screening Recommendation
- Public Comment Sought on Updated Cervical Cancer Screening Recommendations
Notes
- NCI Recognizes Community Physician J. Philip Kuebler
- Meet NCI Experts at the American Public Health Association Annual Meeting
- Summit on Cell Therapy for Cancer Slated for November
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
